Farmas USA

Así es ....y NVAX se movía entre los 7 y 10,50 ....si mal no recuerdo ...

ALXN

Alexion Reports First Quarter 2018 Results 

... and Positive Topline Data from ALXN1210 Phase 3 PNH Switch Study

https://www.businesswire.com/news/home/20180426005430/en/Alexion-Reports-Quarter-2018-Results-Positive-Topline

A mi me da hasta verguenza decir lo que palme 😓😓😓

ACAD

Por cierto, Acadia saca resultados el martes al cierre...

Acadia Healthcare will release its first quarter 2018 earnings on Tuesday, May 1, 2018, after the close of the market.

ACAD

Se confirma hasta en los medios más tocacojones:

CNN confirmed today in a news report that the agency had already begun conducting a new evaluation of the drug. In fact, the report states that the review had begun several weeks ago, which coincides perfectly with the timing of another CNN report that highlighted a growing number of patient deaths and adverse events that may be related to the use of Nuplazid.

https://www.fool.com/investing/2018/04/25/this-explains-why-acadia-pharmaceuticals-is-droppi.aspx

Removiendo bien la herida en este caso:

Hearing that the FDA has opened up an investigation to re-examine Nuplazid certainly isn't good news for investors. The best-case scenario is that the FDA takes another look at the drug and does nothing. The worst case is that they determine that the benefits of using Nuplazid do not outweigh the risks and they decide to pull the drug from the market. If that happens, then the bull case for owning Acadia will be obliterated. 

Which way the agency is going to lean at this point is anyone's guess. Bulls and bears alike should proceed with caution.

La CNBC

Gottlieb told members of Congress he would "take another look" at Nuplazid, CNN reports. The FDA told CNN this week it began conducting a new evaluation of the drug several weeks ago, before Gottlieb was questioned about it.

https://www.cnbc.com/2018/04/25/acadia-shares-plunge-on-report-fda-is-re-examining-its-drug.html

Esto aún no lo he confirmado (estoy en ello), pero indica que la FDA sencillamente va a seguir con lo que hace, famacovigilancia, sin más, y con ello zanja el tema

Y las próxima semana, unas cuántas más.

Estas son las fechas de ER previstas de las que sigo más de cerca (todas "sospechosas habitaules" del foro):

• Acadia  01/05
• Tesaro  03/05
• Horizon  09/05
• Radius  10/05
• Synergy  10/05
• Omeros  31/05
• Progenics  07/06
• TG Therapeutics  07/06 (est.)
• Novavax  13/06 (est.)

ACAD

Lo jodido del tema es que, si se confirma que los riesgos de Nuplazid superan sus beneficios, esto es algo que afecta a todo el pipeline de la compañía, pues está todo basado en el pimavaserin... más allá, no hay nada.

ACAD

Antes lo que quería poner de IV no era lo que he colgado (borro), sino la actualización del  Bank of America Merrill Lynch. Resumen:

Company sees no impact on Nuplazid outlook; Reiterate Buy

  https://www.investorvillage.com/smbd.asp?mb=523&mn=12468&pt=msg&mid=18230253

Del día 19-4 en Parkinson's News Today

#AAN2018 – Real-life Use Supports Nuplazid’s Safety, Efficacy in Treating Parkinson’s Psychosis

https://parkinsonsnewstoday.com/2018/04/19/aan2018-real-life-study-supports-nuplazid-safety-efficacyinparkinsons-psychosis-patients/

Y un estudio del año pasado muy revelador

Update on the treatment of Parkinson’s disease psychosis: role of pimavanserin

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352252/#__ffn_sectitle